Application NumberFunding RecommendationTitleScoreDR2A-05415
Recommended----MSC engineered to produce BDNF for the treatment of Huntington's disease87DR2A-05309
Recommended----Genetic Re-programming of Stem Cells to Fight Cancer84DR2A-05302
Recommended----Treatment of osteoporosis with endogenous Mesenchymal stem cells80DR2A-05423
Recommended----Phase I study of IM Injection of VEGF-Producing MSC for the Treatment of Critical Limb Ischemia79DR2A-05736
Recommended----Neural stem cell transplantation for chronic cervical spinal cord injury 79DR2A-05394
Recommended----Human Embryonic Stem Cell-Derived Cardiomyocytes for Patients with End Stage Heart Failure68DR2A-05320
Not recommended----Progenitor Cells Secreting GDNF for the Treatment of ALS64DR2A-05410
Not recommended----A CIRM Disease Team to Develop Allopregnanolone for Prevention and Treatment of Alzheimer's Disease63DR2A-05416
Not recommended----Restoration of memory in Alzheimer’s disease: a new paradigm using neural stem cell therapy61DR2A-05272
Not recommended----hESC-derived NPCs Programmed with MEF2C for Cell Transplantation in Parkinson’s Disease--DR2A-05288
Not recommended----Genetically Engineered Mesenchymal Stem Cells for the Treatment of Vertebral Compression Fractures.--DR2A-05739
Not recommended----Retinal progenitor cells for treatment of retinitis pigmentosa--DR2A-05365
Not recommended----A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants --DR2A-05368
Not recommended----Development of a Targeted Therapy to Repair Osteoporosis-Related Hip Fractures--DR2A-05352
Not recommended----A New Therapeutic to Reduce CSC Frequency in Breast Cancer--DR2A-05298
Not recommended----Airways for Children--DR2A-05735
Not recommended----Allogeneic Cardiac-Derived Stem Cells for Patients Following a Myocardial Infarction--DR2A-05327
Not recommended----Stem Cell Gene Therapy for HIV in AIDS Lymphoma Patients--DR2A-05373
Not recommended----Recombinant Bispecific Antibody Targeting Cancer Stem Cells for the Therapy of Glioblastoma--DR2A-05737
Not recommended----Phase 3 enabling program for a small molecule in treatment resistant depression and major depressive disorder--